Moreover, MDSCs and Tregs were reported to be associated with resistance to the PD-1 blockade (26, 27), consistent with the poor prognosis of patients with MAP2K1/2-mutated melanoma who received anti-PD-1 therapy. Here, MAP2K1 is linked to melanoma.